Featured Research

from universities, journals, and other organizations

Targeted treatment for prostate cancer to be tested

Date:
April 16, 2010
Source:
University of Cincinnati Academic Health Center
Summary:
Researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors. Researchers will test the efficacy of the AREVA Med 2120lead-antibody when targeted against a specific protein on the surface of the tumor.

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

In the study, UC researchers in the lab of Zhongyun Dong, PhD, will test the efficacy of a new agent targeted against a specific protein on the surface of the tumor.

"It's been shown that human prostate cancer cells overexpress some proteins on their surface," says Dong, an associate professor of hematology oncology in the department of internal medicine. "This overexpression presents a novel target for management of advanced prostate cancer."

Dong says previous radiation therapy targeting these proteins has been shown to inhibit tumor growth in several animal models. UC's study will be the first to explore this approach for prostate tumors. In the work, researchers will bind the isotope 212-lead to an antibody targeting one of these proteins.

"When administered intravenously, the AREVA Med 2120lead-antibody is designed to bind to the tumor's surface, emit alpha particles in and selectively destroy the tumor cells," says Dong.

In the study, expected to run through the end of the year, researchers will measure the toxicity of the treatment and its efficacy in inhibiting cancer cell growth. Data will then be gathered to support phase-1 clinical trials in patients with advanced prostate cancer.

According to hematology oncology professor Olivier Rixe, MD, PhD, the agent represents a more targeted radiation therapy for cancer treatment. Rixe is the director of the UC's recently launched phase-1 clinical trials unit at the newly established Early Drug Development Program.

"Targeting a monoclonal antibody against this protein is not new," says Rixe. "What's new is that we will load the antibody with an isotope that can directly target the protein on the cancer cell and deliver very localized radiation to this specific target of the cancer.

"It's a very interesting concept for drug delivery and a novel strategy for cancer treatment."

Neither Rixe nor Dong report any financial interest in Areva Med.


Story Source:

The above story is based on materials provided by University of Cincinnati Academic Health Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Cincinnati Academic Health Center. "Targeted treatment for prostate cancer to be tested." ScienceDaily. ScienceDaily, 16 April 2010. <www.sciencedaily.com/releases/2010/04/100416185155.htm>.
University of Cincinnati Academic Health Center. (2010, April 16). Targeted treatment for prostate cancer to be tested. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2010/04/100416185155.htm
University of Cincinnati Academic Health Center. "Targeted treatment for prostate cancer to be tested." ScienceDaily. www.sciencedaily.com/releases/2010/04/100416185155.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins